Saltar al contenido
Merck

Gene-corrected p.A30P SNCA patient-derived isogenic neurons rescue neuronal branching and function.

Scientific reports (2021-11-11)
Peter A Barbuti, Jochen Ohnmacht, Bruno F R Santos, Paul M Antony, François Massart, Gérald Cruciani, Claire M Dording, Lukas Pavelka, Nicolas Casadei, Yong-Jun Kwon, Rejko Krüger
RESUMEN

Parkinson's disease (PD) is characterised by the degeneration of A9 dopaminergic neurons and the pathological accumulation of alpha-synuclein. The p.A30P SNCA mutation generates the pathogenic form of the alpha-synuclein protein causing an autosomal-dominant form of PD. There are limited studies assessing pathogenic SNCA mutations in patient-derived isogenic cell models. Here we provide a functional assessment of dopaminergic neurons derived from a patient harbouring the p.A30P SNCA mutation. Using two clonal gene-corrected isogenic cell lines we identified image-based phenotypes showing impaired neuritic processes. The pathological neurons displayed impaired neuronal activity, reduced mitochondrial respiration, an energy deficit, vulnerability to rotenone, and transcriptional alterations in lipid metabolism. Our data describes for the first time the mutation-only effect of the p.A30P SNCA mutation on neuronal function, supporting the use of isogenic cell lines in identifying image-based pathological phenotypes that can serve as an entry point for future disease-modifying compound screenings and drug discovery strategies.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Accutase® solution, sterile-filtered, suitable for cell culture
Sigma-Aldrich
Antimycin A from Streptomyces sp.
Sigma-Aldrich
Anticuerpo anti-tirosina hidroxilasa, Chemicon®, from rabbit
Sigma-Aldrich
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, ≥98% (TLC), powder
Sigma-Aldrich
Monoclonal Anti-MAP2 antibody produced in mouse, clone HM-2, ascites fluid